SHANGHAI, May 1, 2014-- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that the company has received the 2013 Lilly Global Supplier Award. This is the third time that WuXi has been honored with this award from Eli Lilly and Company. This award was established to recognize the exceptional efforts of Lilly's suppliers in providing the company with a competitive advantage. The honor recognizes WuXi AppTec's contributions to Lilly's drug development programs.
"We are honored to receive this award from Lilly in recognition of the skill and hard work of WuXi scientists," said Dr. Ge Li, Chairman and Chief Executive Officer. "This award reflects our commitment to provide high-quality services to Lilly and to all of our 1,700 global customers. We continue our mission to build a broad, integrated platform of R&D services that enables anyone and any company to discover, develop and commercialize healthcare products to benefit patients globally."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Associate Director of Corporate Communications
back to top